Slowing the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes Using Four Pillars of Therapy: The Time to Act is Now.
使用四大療法減緩2型糖尿病患者慢性腎病的進展:行動的時刻就是現在。
Drugs 2024-09-11
Optimizing kidney and cardiovascular protection in an era of multiple effective treatments.
在多種有效治療時代中優化腎臟和心血管保護。
Curr Opin Nephrol Hypertens 2024-08-13
The effects of semaglutide, empagliflozin and their combination on the kidney sodium signal from magnetic resonance imaging: A prespecified, secondary analysis from a randomized, clinical trial.
Semaglutide、empagliflozin及其聯合應用對磁共振成像中腎臟鈉信號的影響:來自一項隨機臨床試驗的預先指定的次要分析。
J Diabetes Complications 2024-02-19
Effects of Oral Semaglutide on Renal Function in Diabetic Kidney Disease: A Short-term Clinical Study.
口服 Semaglutide 對糖尿病腎病的腎功能影響:短期臨床研究。
In Vivo 2024-01-04
Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.
慢性腎臟疾病及其嚴重程度對賽馬魯替胰噴酮在第2型糖尿病患者療效的影響:多中心實務研究。
Front Endocrinol (Lausanne) 2023-11-22
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
糖尿病患者合併使用SGLT2抑制劑、GLP-1受體激動劑和非類固醇MRA,與傳統治療相比,在預估終身心血管、腎臟和死亡益處方面的研究。
Circulation 2024-04-03
Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
結合RAAS和SGLT2抑制劑治療對於非糖尿病蛋白尿性慢性腎病患者的預估終身益處。
Clin J Am Soc Nephrol 2023-12-02
Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
二型糖尿病患者合併慢性腎臟病的鈉葡萄糖共同轉運蛋白-2抑制劑和礦物皮質激素受體拮抗劑聯合治療的心血管和腎臟結果:系統性回顧和網絡荟萃分析。
Diabetes Res Clin Pract 2022-12-21